Biotech M&A Surpasses $106 Billion in 2026 as Big Pharma Races to Replenish Pipelines Before Patent Cliffs 1 day ago AnaIn DealsFunding RoundsInvestmentsPartnerships
Gilead’s Bictegravir/Lenacapavir Combination Wins FDA Priority Review, PDUFA Date Set for August 2026 1 day ago AnaIn FDA ApprovalsResearch UpdatesTop Stories
Definium’s DT120 Delivers Rapid, Durable Antidepressant Effect in Phase 3 EMERGE Trial — LSD Analogue Posts Landmark MDD Results 1 day ago AnaIn Breaking NewsClinical TrialsFeatured AnalysisResearch Updates
Australia’s TGA Grants Conditional Approval to Iovance’s Lifileucel — A First for T Cell Therapy in Solid Tumour Oncology 1 day ago AnaIn BreakthroughsClinical TrialsFeatured AnalysisInnovation
FDA Approves AstraZeneca’s Truqap Combination as First Targeted Therapy for PTEN-Deficient Metastatic Prostate Cancer 1 day ago AnaIn Breaking NewsFDA ApprovalsResearch Updates
Bemdaneprocel Phase I Data Show Sustained Motor Benefits at 36 Months in Parkinson’s Disease, Advancing Case for Cell Replacement 7 days ago AnaIn Biopharma HighlightsClinical Trials
NewLimit Raises $435 Million on Evidence of Age Reversal in Human Liver Cells, Plans First Clinical Trial 1 week ago AnaIn DealsFunding RoundsVenture Capital
FDA Approves First Oral Carbapenem for Complicated Urinary Tract Infections, Ending Decades of IV Dependency 1 week ago AnaIn FDA ApprovalsResearch Updates
Neurona Therapeutics Plans Phase 3 EPIC Trial After Rezanecel Shows Durable Seizure Reduction in 31-Patient Phase 1/2 Dataset 1 week ago AnaIn Biopharma HighlightsClinical Trials
Eli Lilly’s $7.8 Billion Centessa Deal Extends Neuroscience Ambitions into Orexin Signalling and Excessive Daytime Sleepiness 1 week ago AnaIn PartnershipsResearch Updates
FDA Clears First PROTAC Drug in History: Vepdegestrant Resets the Bar for ESR1-Mutant Breast Cancer Treatment 1 week ago AnaIn Breaking NewsClinical TrialsFDA Approvals
FDA Approves Xocova as First Oral Drug for COVID-19 Post-Exposure Prophylaxis 2 weeks ago AnaIn Biopharma HighlightsFDA ApprovalsResearch Updates
Isomorphic Labs Closes $2.1 Billion Series B to Push AI-Designed Drugs Toward First Clinical Trials 2 weeks ago AnaIn DealsFunding RoundsPartnerships
Stoke-Biogen Dravet Drug Cuts Seizures by 91% in Long-Term Data as Phase 3 Enrolment Wraps 2 weeks ago AnaIn Clinical TrialsTop Stories
Biotech M&A Reaches $106 Billion in 2026 as Patent Cliff Pressure and Recovering Markets Drive Record Deal Pace 2 weeks ago AnaIn DealsFunding RoundsPartnerships
